Kyverna Therapeutics, Inc.
KYTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $97 | $35 | $38 | $76 |
| Short-Term Investments | $189 | $23 | $14 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $3 | $2 | $1 |
| Total Curr. Assets | $291 | $61 | $53 | $77 |
| Property Plant & Equip (Net) | $11 | $11 | $12 | $8 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $5 | $4 | $1 | $1 |
| Total NC Assets | $16 | $15 | $14 | $8 |
| Other Assets | -$2 | $0 | $0 | $0 |
| Total Assets | $305 | $75 | $67 | $85 |
| Liabilities | – | – | – | – |
| Payables | $5 | $4 | $1 | $1 |
| Short-Term Debt | $4 | $3 | $2 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $6 |
| Other Curr. Liab. | $25 | $13 | $8 | $8 |
| Total Curr. Liab. | $34 | $20 | $12 | $16 |
| LT Debt | $4 | $6 | $8 | $5 |
| Deferred Rev, NC | $0 | $0 | $0 | $1 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $110 |
| Total NC Liab. | $4 | $6 | $8 | $116 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $8 | $9 | $11 | $6 |
| Total Liabilities | $38 | $26 | $20 | $132 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $181 | $121 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$264 | -$136 | -$76 | -$47 |
| AOCI | $0 | $0 | -$0 | $0 |
| Other Equity | $530 | $5 | $2 | $1 |
| Total Equity | $267 | $49 | $47 | -$46 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $305 | $75 | $67 | $85 |
| Net Debt | -$88 | -$26 | -$27 | -$71 |